Inhalation Sciences AB (ISAB) has announced that former ExScale Bio CEO Manoush Masarrat, who has been a member of the ISAB board of directors since January 2019, will succeed Lena Heffler as ISAB CEO. In addition to his most recent position as CEO of ExScale Bio, Masarrat has also served in sales and marketing roles at a number of companies, including Medical Vision, Electrocore, and ArthroCare.
According to the company, Heffler has resigned from the CEO position for personal reasons but will remain with the company for six months, “focusing on her core areas of expertise; marketing, sales and project management.”
Earlier this year, ISAB announced that it is taking steps to validate its PreciseInhale precision aerosol dosing system for clinical use, a process the company said it expects to complete by about September 2020.
Masarrat commented, “PreciseInhale is a clear leader in its niche, as proven by its strong customer base of many large and established companies. From that base I want to help ISAB up to the next level. For me that means broader commercial partnerships and agreements. Our technology being validated for clinical use opens up the opportunity for us to make a serious difference in the development of new inhalable drugs.”
ISAB Chairman of the Board Fredrik Sjövall said, “We are very pleased that Manoush has decided to step up as CEO of Inhalation Sciences. Manoush has exactly the right background, character and drive to continue developing PreciseInhale into a world-leading platform for the development of new inhaled drugs. That he been able and willing to take up the role at such short notice is superb. Manoush knows the company from a strategic perspective, and with Lena remaining with us in the company during the interim period we have excellent conditions to get the new role operational quickly and efficiently.”
Read the Inhalation Sciences press release.
